A Telling Report
The Institute for Safe Medical Practices (ISMP) issued a report in May 2015 that revealed more than 450 patients taking Invokana reported several different kidney problems. These included:
- Renal impairment
- Kidney stones
- Unexpected loss of weight
- Kidney failure
Invokana is part of a class of drugs known as SGLT2 (sodium glucose co-transporter 2) inhibitors. Other SGLT2 inhibitors include Invokamet, Glyxambi, Xigduo XR, Farxiga and Jardiance. Diabetics use these drugs to help eliminate excess sugar from the body through urination.
However, these medications have an impact on the functions of the kidneys. The ISMP report revealed that at least 54 patients who were taking Invokana suffered at least some level of renal impairment or failure. It raises the question of whether the manufacturer of the drug – Johnson & Johnson subsidiary Janssen Pharmaceuticals – withheld information regarding Invokana and the risk of kidney complications.
The Dangers of Kidney Failure
When kidneys fail, they are no longer able to properly filter waste from the blood. As a result, a wide variety of health complications – including death – can occur. Symptoms include:
- Chest pain
- Shortness of breath
In some cases, kidney failure can lead to permanent damage, requiring either a transplant or dialysis. If not treated quickly enough, kidney failure can be fatal.